Key presentations at ASCO today on advanced prostate cancer

The key prostate cancer presentations today at the annual meeting of the American Society of Clinical Oncology (ASCO) were all given at a morning session on high-risk and advanced prostate cancer.

Abiraterone acetate in chemotherapy-naive mCRPC — Phase III trial outcome

This morning, at the ASCO annual meeting, Dr. Charles Ryan will present the full interim results of COU-AA-302, the randomized, Phase III study of abiraterone acetate in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC).

Nearly 100 drugs in development for treatment of prostate cancer in USA

According to a new report just issued by PhRMA, the pharmaceutical company trade group believes there are currently a total of 94 drugs in clinical development by its members specifically for the treatment of some form of prostate cancer.

Two important new trials of enzalutamide and cabozantinib for patients with mCRPC

According to media releases from the relevant companies, two significant trials (of enzalutamide and of cabozantinib) are already or will soon be recruiting men with metastatic, castration-resistant prostate cancer (mCRPC).

Managing advanced prostate cancer: what’s going to be presented at ASCO

So there are going to be > 180 papers specific to the management of prostate cancer presented at the annual meeting of the American Society of Clinical Oncology (ASCO) starting in Chicago next weekend. Some will be trivial; several will be “interesting”; a very few will be important.

GUMDROP — or how some specialists collaborate to help their patients

An article in The Washington Post today discusses an initiative through which a group of about 40 specialists in the management of advanced forms of genitourinary cancers (including prostate cancer) get together to share ideas and knowledge to help their patients.

Update on Phase III trial of tasquinimod in mCRPC

According to a media release issued this morning by Active Biotech and Ipsen, the companies have already enrolled 600 out of the 1,200 men with metastatic, castration-resistant prostate cancer (mCRPC) needed to complete the randomized, double-blind Phase III clinical trial of tasquinimod.

NICE issues new and positive draft guidance on abiraterone acetate

According to information on the web site of the National Institute for Clinical Excellence (NICE), revised draft guidance has been issued by NICE regarding the routine use of abiraterone acetate.

Abiraterone acetate may help to eliminate cancer prior to surgery in some men with high-risk, localized disease

According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical [...]

Can adhesion receptor blockade lower risk for metastatic prostate cancer?

A group of Finnish researchers have reported the apparent existence of a series of genes that are capable of inhibiting the spread (metastasis) of prostate cancer cells — at least in the laboratory.

Abiraterone acetate in chemotherapy-naïve mCRPC: data at ASCO

According to an article in the online issue of Oncology Business Review (see page 12 of OBR Green), the full results of the clinical trial of abiraterone acetate + prednisone vs. placebo + prednisone in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer (mCRPC) will — as previously suggested — be presented at the upcoming annual [...]

GTx-758 to be tested at lower doses in men with mCRPC

According to a media release issued yesterday by GTx, Inc., the U.S. Food & Drug Administration is allowing the company to proceed with a proposed, open-label, Phase II clinical trial of Capesaris® — also known as GTX-758 — in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC).

Video presentation/discussion about new drugs in development

For those who are interested in seeing a 30-minute video of a presentation and discussion about the development of new drugs like abiraterone, MDV3100, TAK-700 (orteronel), and others, just click here. This video comes from a continuing medical education activity presented in association with the Genitourinary Cancers symposium in San Francisco back in February.

PTEN, MAN2C1, and the identification of potentially aggressive forms of prostate cancer

A new article in Nature Communications has suggested that we may be able to specifically identify some aggressive forms of prostate cancer cells that come with high risk for metastatic prostate cancer even at low PSA levels and other less aggressive forms of prostate cancer cell.

Is combining abiraterone acetate with MDV3100 going to be clinically beneficial in mCRPC?

An article just published in Cancer Research this week suggests that adding the investigational agent enzalutamide (MDV3100) to abiraterone acetate and prednisone in men being treated for metastatic, castration-resistant prostate cancer (mCRPC) may be able to further delay disease progression among men showing signs of progression after initial treatment with abiraterone acetate.

Follow

Get every new post delivered to your Inbox.

Join 333 other followers